Kacena KA and Chen P. Group Sequential Adaptive Survival Trials: Design and Analysis with Case Studies (In Review) 

Bushnell, Jr. DL, O’Dorisio TM, O'Dorisio MS, Menda Y, Hicks RJ, Van Cutsem E, Baulieu JL, Borson-Chazot F, Anthony L, Benson AB, Oberg K, Grossman AB, Connolly M, Bouterfa H, Li Y, Kacena KA, LaFrance ND, Pauwels SA. 90Y-Edotreotide for Metastatic Carcinoid Refractory to Octreotide. JCO 2010; 28: 1652-1659. 

Bultron G, Kacena KA, Pearson D, Boxer M, Yang R, Sathe S, Pastores G, Mistry PK. The risk of Parkinson's disease in type 1 Gaucher disease. J Inherit Metab Dis. 2010; 33:167-173.

Kontos MC, Weiland F, DePuey G, Mahmarian JJ, Iskandrian A, Bateman T, Heller GV, Ananthasubramanam K, Li Y, Goldman JL, Armor T, Kacena KA, LaFrance ND, Dilsizian V, Garcia EV, Babich JW, and Udelson JE. Iodofiltic Acid I 123 (BMIPP) Fatty Acid Imaging Improves Initial Diagnosis in Emergency Department Patients with Suspected Acute Coronary Syndromes: A Multicenter Trial. J Am Coll Cardiol. 2010; 56:290-299.

*Grabowski GA, *Kacena KA, Cole A, Hollak CEM, Zhang L, Yee J, Mistry PK, Zimran A, Charrow J, and vom Dahl S. Dose-Response Relationships for Enzyme Replacement Therapy with Imiglucerase/Alglucerase in Patients with Gaucher Disease Type 1. Genet Med. 2009; 11:92-100. * Noted on publication that both authors contributed equally.

*Taddei TH, *Kacena KA, Yang M, Yang R, Malhotra A, Boxer M, Aleck KA, Rennert G, Pastores GM, Mistry PK.  The under-recognized progressive nature of N370S Gaucher Disease and high risk of cancer in 403 patients. Am J Hematol. 2009; 84:208-14. * Noted on publication that both authors contributed equally.

Weinreb NJ, Deegan P, Kacena KA, Mistry P, Pastores GM, Velentgas P, and vom Dahl S. Life expectancy in Gaucher disease type 1. Am. J. Hematol 2008; 83: 896–900.

Andersson HC, Kaplan P, Kacena KA, and Yee J. Clinical outcome following 8-year enzyme replacement therapy in 884 children with type 1 Gaucher disease (GD1). Molecular Genetics and Metabolism 2008; 93: 14-19.

Wenstrup R, Kacena KA, Kaplan P, Pastores G, Prakash-Cheng A, Zimran A, and Handgartner T. Bone mineral density and fractures in type 1 Gaucher disease. J Bone Miner Res 2007; 21: 119–126.

Kaplan P, Andersson HC, Kacena KA, and Yee J. Pediatric characteristics of Gaucher Disease at the time of Diagnosis. Arch Pediatr Adolesc Med 2006; 160: 603-8.

Rosenbloom B, Weinreb N, Zimran A, Kacena KA, Charrow J, and Ward E. Cancer incidence and Gaucher disease. Blood2005; 105: 4569-72.

Kacena KA, Dohnal K, Benesova V, Grivna M, Deliopolu J, Tryzna R, Horak J, Gaydos CA, and Quinn TC. Chlamydia, gonorrhea, and HIV-1 prevalence among five populations in the Czech and Slovak Republics. Sex Trans Dis 2001; 28: 356-62.

Kacena KA, Quinn SB, Hartman SC, Quinn TC, and Gaydos CA. Pooling urine samples for screening for Neisseria gonorrhoeae by ligase chain reaction: accuracy and application. J Clin Microbiol 1998; 36: 3624-8.

Kacena KA, Quinn TC, Howell MR, Quinn SB, Madico GE, and Gaydos CA. Pooling urine samples for ligase chain reaction screening for genital Chlamydia trachomatis infection in asymptomatic women. J Clin Microbiol 1998; 36: 481-5.

Kacena KA.  Detection of infectious disease in resource-poor settings: chlamydia, gonorrhea, and HIV-1 in the Czech and Slovak Republics.  1998.  Dissertation.

Smith MN, Grivna M, and Kacena KA. Childhood injury models and prevention in the United States. Cesko-Slovenska Pediatrie 1996; 51: 242-5. 

Madico G, Gilman RH, Checkley W, Cabrera L, Kohlstadt I, Kacena KA, Diaz JF, and Black R.  Tuberculin sensitivity in contact and control Peruvian children: the community infection ratio as an indicator for tuberculin control. Lancet 1995; 345: 416-9.

Gonzales AE, Gilman RH, Garcia HH, McDonald J, Kacena KA, Tsang VCW, Pilcher JB, Suarez F, Cavida C, Miranda E, and the Cysticercosis Working Group in Peru. Use of sentinel pigs to monitor environmental Taenia solium contamination. Am J Trop Med Hyg1994; 5: 847-50.